PMC:6537946 / 6046-7214 JSONTXT

{"project":"0_colil","denotations":[{"id":"31106338-2883575-6263","span":{"begin":223,"end":225},"obj":"2883575"},{"id":"31106338-16534009-6264","span":{"begin":602,"end":604},"obj":"16534009"},{"id":"31106338-25176015-6265","span":{"begin":1164,"end":1166},"obj":"25176015"}],"text":"Pharmacological treatment\nThe CONSENSUS trial investigated ‘enalapril’ more than 30 years ago; it was the first systematic evaluation of lowering the number of heart failure-associated deaths via pharmacological treatment [16]. Since then, various substances have proven effective. Postulating an annual mortality rate of 20% and a mean survival time of 4.1 years at baseline, adding an angiotensin-converting enzyme inhibitor, beta-blocker, aldosterone antagonist and an implantable cardioverter-defibrillator (ICD) decreases annual mortality by 70% and lengthens the mean survival time by 5.6 years [17]. Results from the recently published PARADIGM-HF [Prospective Comparison of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) with ACEI (Angiotensin-Converting–Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure] trial demonstrated an improvement in the mortality rate in response to applying new pharmacological treatment options. Sacubitril-valsartan proved superior in reducing the risks of death and hospitalization for heart failure compared to standard medical treatment by interacting with the neurohumoral system [18]."}

{"project":"TEST0","denotations":[{"id":"31106338-197-203-6263","span":{"begin":223,"end":225},"obj":"[\"2883575\"]"},{"id":"31106338-235-241-6264","span":{"begin":602,"end":604},"obj":"[\"16534009\"]"},{"id":"31106338-190-196-6265","span":{"begin":1164,"end":1166},"obj":"[\"25176015\"]"}],"text":"Pharmacological treatment\nThe CONSENSUS trial investigated ‘enalapril’ more than 30 years ago; it was the first systematic evaluation of lowering the number of heart failure-associated deaths via pharmacological treatment [16]. Since then, various substances have proven effective. Postulating an annual mortality rate of 20% and a mean survival time of 4.1 years at baseline, adding an angiotensin-converting enzyme inhibitor, beta-blocker, aldosterone antagonist and an implantable cardioverter-defibrillator (ICD) decreases annual mortality by 70% and lengthens the mean survival time by 5.6 years [17]. Results from the recently published PARADIGM-HF [Prospective Comparison of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) with ACEI (Angiotensin-Converting–Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure] trial demonstrated an improvement in the mortality rate in response to applying new pharmacological treatment options. Sacubitril-valsartan proved superior in reducing the risks of death and hospitalization for heart failure compared to standard medical treatment by interacting with the neurohumoral system [18]."}

{"project":"2_test","denotations":[{"id":"31106338-2883575-28904576","span":{"begin":223,"end":225},"obj":"2883575"},{"id":"31106338-16534009-28904577","span":{"begin":602,"end":604},"obj":"16534009"},{"id":"31106338-25176015-28904578","span":{"begin":1164,"end":1166},"obj":"25176015"}],"text":"Pharmacological treatment\nThe CONSENSUS trial investigated ‘enalapril’ more than 30 years ago; it was the first systematic evaluation of lowering the number of heart failure-associated deaths via pharmacological treatment [16]. Since then, various substances have proven effective. Postulating an annual mortality rate of 20% and a mean survival time of 4.1 years at baseline, adding an angiotensin-converting enzyme inhibitor, beta-blocker, aldosterone antagonist and an implantable cardioverter-defibrillator (ICD) decreases annual mortality by 70% and lengthens the mean survival time by 5.6 years [17]. Results from the recently published PARADIGM-HF [Prospective Comparison of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) with ACEI (Angiotensin-Converting–Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure] trial demonstrated an improvement in the mortality rate in response to applying new pharmacological treatment options. Sacubitril-valsartan proved superior in reducing the risks of death and hospitalization for heart failure compared to standard medical treatment by interacting with the neurohumoral system [18]."}

{"project":"MyTest","denotations":[{"id":"31106338-2883575-28904576","span":{"begin":223,"end":225},"obj":"2883575"},{"id":"31106338-16534009-28904577","span":{"begin":602,"end":604},"obj":"16534009"},{"id":"31106338-25176015-28904578","span":{"begin":1164,"end":1166},"obj":"25176015"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Pharmacological treatment\nThe CONSENSUS trial investigated ‘enalapril’ more than 30 years ago; it was the first systematic evaluation of lowering the number of heart failure-associated deaths via pharmacological treatment [16]. Since then, various substances have proven effective. Postulating an annual mortality rate of 20% and a mean survival time of 4.1 years at baseline, adding an angiotensin-converting enzyme inhibitor, beta-blocker, aldosterone antagonist and an implantable cardioverter-defibrillator (ICD) decreases annual mortality by 70% and lengthens the mean survival time by 5.6 years [17]. Results from the recently published PARADIGM-HF [Prospective Comparison of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) with ACEI (Angiotensin-Converting–Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure] trial demonstrated an improvement in the mortality rate in response to applying new pharmacological treatment options. Sacubitril-valsartan proved superior in reducing the risks of death and hospitalization for heart failure compared to standard medical treatment by interacting with the neurohumoral system [18]."}

{"project":"testtesttest","denotations":[{"id":"T172","span":{"begin":160,"end":165},"obj":"Body_part"},{"id":"T176","span":{"begin":840,"end":845},"obj":"Body_part"},{"id":"T180","span":{"begin":1066,"end":1071},"obj":"Body_part"},{"id":"T184","span":{"begin":1156,"end":1162},"obj":"Body_part"}],"attributes":[{"id":"A172","pred":"uberon_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A173","pred":"uberon_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"A174","pred":"uberon_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"A175","pred":"uberon_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/UBERON_0015230"},{"id":"A176","pred":"uberon_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A177","pred":"uberon_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"A178","pred":"uberon_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"A179","pred":"uberon_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/UBERON_0015230"},{"id":"A180","pred":"uberon_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A181","pred":"uberon_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"A182","pred":"uberon_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"A183","pred":"uberon_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/UBERON_0015230"},{"id":"A184","pred":"uberon_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/UBERON_0000467"}],"text":"Pharmacological treatment\nThe CONSENSUS trial investigated ‘enalapril’ more than 30 years ago; it was the first systematic evaluation of lowering the number of heart failure-associated deaths via pharmacological treatment [16]. Since then, various substances have proven effective. Postulating an annual mortality rate of 20% and a mean survival time of 4.1 years at baseline, adding an angiotensin-converting enzyme inhibitor, beta-blocker, aldosterone antagonist and an implantable cardioverter-defibrillator (ICD) decreases annual mortality by 70% and lengthens the mean survival time by 5.6 years [17]. Results from the recently published PARADIGM-HF [Prospective Comparison of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) with ACEI (Angiotensin-Converting–Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure] trial demonstrated an improvement in the mortality rate in response to applying new pharmacological treatment options. Sacubitril-valsartan proved superior in reducing the risks of death and hospitalization for heart failure compared to standard medical treatment by interacting with the neurohumoral system [18]."}